Antje Prasse

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5906639/publications.pdf

Version: 2024-02-01

145 papers	7,622 citations	61984 43 h-index	56724 83 g-index
157 all docs	157 docs citations	157 times ranked	8812 citing authors

#	Article	IF	Citations
1	A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia. Pneumologie, 2022, 76, 25-34.	0.1	0
2	BAL Transcriptomes Characterize Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Impact. Chest, 2022, 161, 1576-1588.	0.8	8
3	Increased regional ventilation as early imaging marker for future disease progression of interstitial lung disease: a feasibility study. European Radiology, 2022, 32, 6046-6057.	4.5	4
4	Treating sarcoidosis and potential new drugs. , 2022, , 328-336.		2
5	A Phase IIb Randomized Clinical Study of an Anti-Î±_vÎ²₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1128-1139.	5.6	29
6	Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 1094-1106.	0.8	23
7	Immunmodulation bei autoimmunen interstitiellen Lungenerkrankungen. Karger Kompass Autoimmun, 2021, 3, 2-9.	0.0	0
8	Role of endothelial microRNA 155 on capillary leakage in systemic inflammation. Critical Care, 2021, 25, 76.	5.8	7
9	Quantification of dual-energy CT-derived functional parameters as potential imaging markers for progression of idiopathic pulmonary fibrosis. European Radiology, 2021, 31, 6640-6651.	4.5	12
10	Integrative analysis of cell state changes in lung fibrosis with peripheral protein biomarkers. EMBO Molecular Medicine, 2021, 13, e12871.	6.9	53
11	Lung microbiome composition and bronchial epithelial gene expression in patients with COPD versus healthy individuals: a bacterial 16S rRNA gene sequencing and host transcriptomic analysis. Lancet Microbe, The, 2021, 2, e300-e310.	7.3	60
12	The NLRP3-Inflammasome-Caspase-1 Pathway Is Upregulated in Idiopathic Pulmonary Fibrosis and Acute Exacerbations and Is Inducible by Apoptotic A549 Cells. Frontiers in Immunology, 2021, 12, 642855.	4.8	27
13	Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways. International Journal of Molecular Sciences, 2021, 22, 5696.	4.1	8
14	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 476-486.	10.7	254
15	Gender specific airway gene expression in COPD sub-phenotypes supports a role of mitochondria and of different types of leukocytes. Scientific Reports, 2021, 11, 12848.	3.3	8
16	Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis. European Respiratory Journal, 2021, 58, 2002950.	6.7	29
17	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 9960-9988.	6.4	26
18	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. Respiration, 2021, 100, 238-271.	2.6	19

#	Article	IF	Citations
19	Granulomatousâ€“lymphocytic interstitial lung disease: an international research prioritisation. ERJ Open Research, 2021, 7, 00467-2021.	2.6	6
20	Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis. Inflammation, 2020, 43, 1-7.	3.8	56
21	Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 370-380.	5.7	37
22	Managing Granulomatousâ€“Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. Frontiers in Immunology, 2020, 11, 606333.	4.8	10
23	Immunomodulation in Autoimmune Interstitial Lung Disease. Respiration, 2020, 99, 819-829.	2.6	4
24	Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	21
25	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. European Respiratory Journal, 2020, 56, 1902279.	6.7	102
26	Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial. Journal of Clinical Medicine, 2020, 9, 1567.	2.4	21
27	Presence of Antibodies Binding to Negative Elongation Factor E in Sarcoidosis. Journal of Clinical Medicine, 2020, 9, 715.	2.4	3
28	Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosisâ€”Part B. Journal of Clinical Medicine, 2020, 9, 1993.	2.4	10
29	Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. Journal of Clinical Medicine, 2020, 9, 1940.	2.4	18
30	The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation. European Respiratory Journal, 2020, 55, 1900119.	6.7	51
31	Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor. European Journal of Internal Medicine, 2020, 78, 58-62.	2.2	23
32	The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2020, 55, 2000085.	6.7	148
33	Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease. Frontiers in Immunology, 2020, 11, 616832.	4.8	12
34	CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer. Cellular Signalling, 2020, 73, 109672.	3.6	28
35	Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Frontiers in Medicine, 2020, 7, 601279.	2.6	24
36	Combined assessment of regional lung function and morphology using a contrast enhanced Dual-Energy CT protocol: Prospective value of functional imaging biomarkers in longitudinal analysis of patients with Interstitial Lung Disease. , 2020, , .		0

#	Article	IF	Citations
37	Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial. , 2020, , .		1
38	Temporal subtraction of serial CT scans for visualisation and quantification of disease progression in Idiopathic Pulmonary Fibrosis. , 2020, , .		0
39	BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 622-630.	5.6	121
40	A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2019, 5, 151-163.	2.2	9
41	POINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? Yes. Chest, 2019, 156, 203-205.	0.8	2
42	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine,the, 2019, 7, 771-779.	10.7	65
43	Rebuttal From Dr Prasse. Chest, 2019, 156, 208-209.	0.8	0
44	MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis. Journal of Biological Chemistry, 2019, 294, 5008-5022.	3.4	29
45	The Ariane-IPF ERS Clinical Research Collaboration: seeking collaboration through launch of a federation of European registries on idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1900539.	6.7	8
46	The FMS-like tyrosine kinase-3 ligand/lung dendritic cell axis contributes to regulation of pulmonary fibrosis. Thorax, 2019, 74, 947-957.	5.6	24
47	The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respiratory Research, 2019, 20, 59.	3.6	73
48	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Research, 2019, 5, 00124-2019.	2.6	33
49	High degree of polyclonality hinders somatic mutation calling in lung brush samples of COPD cases and controls. Scientific Reports, 2019, 9, 20158.	3.3	1
50	OUP accepted manuscript. Rheumatology, 2019, 58, 165-178.	1.9	18
51	Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial. , 2019, , .		3
52	Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry. , 2019, , .		1
53	Single Cell RNA Sequencing profiles Distinct BAL Cell Subpopulations in Sarcoidosis. , 2019, , .		1
54	The Transciptome of BAL Cells at Acute Exacerbation of IPF reveals New Insights. , 2019, , .		1

#	Article	IF	Citations
55	Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF). , 2019, , .		10
56	Transciptomic Profile TGF-Î² Inhibitor Treatment in BAL Cells from IPF Patients. Pneumologie, 2019, 73, .	0.1	0
57	Serum CCL18 Levels Predict Survival and Disease Progression in IPF Patients Treated with Antifibrotic Drugs. , 2019, 73, .		0
58	Key Role of HDAC6 Overexpression in the Migration, Proliferation and Fibrotic Remodelling by Airway Basal Cells. , 2019, 73, .		0
59	Role of autocrine factors produced by aiway basal cells in a 3D Organoid model testing bronchosphere generation which resembles epithelial remodeling processes in IPF. , 2019, , .		0
60	Close correlation between cumulative corticosteroid dose and weight gain in a German cohort of sarcoid patients. , 2019, , .		0
61	German Guideline for Idiopathic Pulmonary Fibrosis â€“ Update on Pharmacological Therapies 2017. Pneumologie, 2018, 72, 155-168.	0.1	47
62	Phenotypes of organ involvement in sarcoidosis. European Respiratory Journal, 2018, 51, 1700991.	6.7	146
63	Gene Network Analysis of Interstitial Macrophages After Treatment with Induced Pluripotent Stem Cells Secretome (iPSC-cm) in the Bleomycin Injured Rat Lung. Stem Cell Reviews and Reports, 2018, 14, 412-424.	5.6	14
64	Sarcoidosis: a review for the internist. Internal and Emergency Medicine, 2018, 13, 325-331.	2.0	88
65	CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer. Anticancer Research, 2018, 38, 3913-3918.	1.1	6
66	Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2018, 24, 2277-2284.	2.0	19
67	Genetic Profiles of Clinical Features in Sarcoidosis. , 2018, , .		1
68	BAL cell transcriptome predicts survival in IPF and can be used to gauge and model treatment effects interfering with the TGF-beta pathway. , 2018, , .		2
69	A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment. , 2018, , .		1
70	Diagnosis and therapy of acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in Germany. , 2018, , .		2
71	Trace metals in fluids lining the respiratory system of patients with idiopathic pulmonary fibrosis and diffuse lung diseases. Journal of Trace Elements in Medicine and Biology, 2017, 42, 39-44.	3.0	19
72	Transcriptome profiles in sarcoidosis and their potential role in disease prediction. Current Opinion in Pulmonary Medicine, 2017, 23, 487-492.	2.6	26

#	Article	IF	Citations
73	Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respiratory Medicine,the, 2017, 5, 857-868.	10.7	115
74	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulmonary Medicine, 2017, 17, 122.	2.0	94
75	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory Research, 2017, 18, 139.	3.6	135
76	Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome. PLoS ONE, 2017, 12, e0180859.	2.5	33
77	Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)?. PLoS ONE, 2017, 12, e0185350.	2.5	5
78	In Reply. Deutsches Ärzteblatt International, 2017, 114, 120.	0.9	0
79	Exacerbations, hospitalisations and mortality in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry. , 2017, , .		0
80	Transcriptional Profiling reveals Reprogramming of Airway Basal Cells in IPF. , 2017, , .		0
81	Gender associated Differences in Patients with IPF based on the Analysis of the INSIGHTS-IPF Registry Data. , 2017, , .		0
82	The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis. Deutsches Ärzteblatt International, 2016, 113, 565-74.	0.9	72
83	Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration, 2016, 92, 98-106.	2.6	52
84	Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 749-757.	2.9	29
85	Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography. European Respiratory Journal, 2016, 48, 92-103.	6.7	46
86	Impairment of Immunoproteasome Function by Cigarette Smoke and in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1230-1241.	5.6	42
87	Effects of a 3-week pulmonary rehabilitation program in patients with idiopathic pulmonary fibrosis â€“ A randomized, controlled trial. , 2016, , .		2
88	Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry. , 2016, , .		2
89	Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis. PLoS ONE, 2016, 11, e0147258.	2.5	63
90	C-type Lectin Mincle Recognizes Glucosyl-diacylglycerol of Streptococcus pneumoniae and Plays a Protective Role in Pneumococcal Pneumonia. PLoS Pathogens, 2016, 12, e1006038.	4.7	51

#	Article	IF	Citations
91	GranulomatÃ¶se Erkrankungen. , 2016, , 169-184.		0
92	Interstitielle Lungenerkrankung bei CVID. , 2016, , 277-281.		0
93	LSC Abstract â€“ Network analysis of induced pluripotent stem cells secretome reveales its anti fibrotic action in rat lung injury model. , 2016, , .		0
94	LATE-BREAKING ABSTRACT: Molecular imaging with CXCR4-gallium-68-pentixafor PET correlates with GAP index and treatment effects in idiopathic pulmonary fibrosis. , 2016, , .		0
95	LSC Abstract â€“ Network analysis of induced pluripotent stem cells secretome reveales its anti fibrotic action in rat lung injury model. , 2016, , .		0
96	Nintedanib for idiopathic pulmonary fibrosis (IPF): Data from the German compassionate use program (CUP). , 2016, , .		0
97	Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0116775.	2.5	170
98	Prognostic Value of Malic Enzyme and ATP-Citrate Lyase in Non-Small Cell Lung Cancer of the Young and the Elderly. PLoS ONE, 2015, 10, e0126357.	2.5	33
99	Immune response to Propionibacterium acnes in patients with sarcoidosis â€“ in vivo and in vitro. BMC Pulmonary Medicine, 2015, 15, 75.	2.0	37
100	â€œSarcoidosis: Recent Advancesâ€• Seminars in Respiratory and Critical Care Medicine, 2014, 35, 283-284.	2.1	0
101	Bronchoalveolar lavage cytology resembles sarcoidosis in a subgroup of granulomatous CVID. European Respiratory Journal, 2014, 43, 922-924.	6.7	16
102	Sarcoidosis. Lancet, The, 2014, 383, 1155-1167.	13.7	900
103	A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls. Proteomics - Clinical Applications, 2014, 8, 932-950.	1.6	57
104	Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. European Respiratory Journal, 2014, 43, 1530-1532.	6.7	54
105	Nontransformed, GM-CSFâ€“dependent macrophage lines are a unique model to study tissue macrophage functions. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2191-8.	7.1	91
106	Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care and Research, 2013, 65, 281-287.	3.4	15
107	The pathogenesis of pulmonary fibrosis: a moving target. European Respiratory Journal, 2013, 41, 1207-1218.	6.7	252
108	Common variable immunodeficiency-associated granulomatous and interstitial lung disease. Current Opinion in Pulmonary Medicine, 2013, 19, 503-509.	2.6	66

#	Article	IF	Citations
109	Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation. PLoS ONE, 2013, 8, e81382.	2.5	102
110	Biomarkers. , 2013, , 90-95.		0
111	The EvA study: aims and strategy. European Respiratory Journal, 2012, 40, 823-829.	6.7	29
112	CCL18 â€" Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis. Journal of Rheumatology, 2012, 39, 1407-1412.	2.0	14
113	Pathogenesis of sarcoidosis. Presse Medicale, 2012, 41, e275-e287.	1.9	44
114	Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7853-7858.	7.1	306
115	The impact of gas exchange measurement during exercise in pulmonary sarcoidosis. Respiratory Medicine, 2011, 105, 122-129.	2.9	26
116	Increase In Inflammasome Activation Of Alveolar Macrophages In Pulmonary Fibrosis. , 2011, , .		0
117	Calgranulin B (S100A9/MRP14): A Key Molecule in Idiopathic Pulmonary Fibrosis?. Inflammation, 2011, 34, 85-91.	3.8	32
118	Whole-Blood Flow-Cytometric Analysis of Antigen-Specific CD4 T-Cell Cytokine Profiles Distinguishes Active Tuberculosis from Non-Active States. PLoS ONE, 2011, 6, e17813.	2.5	109
119	Alternatively activated alveolar macrophages in pulmonary fibrosisâ€"mediator production and intracellular signal transduction. Clinical Immunology, 2010, 137, 89-101.	3.2	268
120	Peripheral Mucosa-homing T Cells In Fibrosis Patients Preferentially Release Th2 Cytokines. , 2010, , .		0
121	Safety and Efficacy of an Inhaled Epidermal Growth Factor Receptor Inhibitor (BIBW 2948 BS) in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 438-445.	5.6	82
122	M2 Marker Expression By Alveolar Macrophages Predicts Survival In IPF. , 2010, , .		0
123	Immunologic Response of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 390-403.	2.1	82
124	Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 540-548.	5.6	146
125	Fatal adult-onset antibody deficiency syndrome in a patient with cartilage hair hypoplasia. Human Immunology, 2010, 71, 916-919.	2.4	8
126	Pulmonary Graft-Versus-Host Disease After Reduced Toxicity Conditioning with Fludarabin, Carmustine and Melphalan Prior to Hematopoietic Stem Cell Transplantation. Blood, 2010, 116, 1266-1266.	1.4	0

#	Article	IF	Citations
127	Circulating CD21^{low}B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13451-13456.	7.1	308
128	Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 717-723.	5.6	290
129	CCL18 Production is Decreased in Alveolar Macrophages from Cigarette Smokers. Inflammation, 2009, 32, 163-168.	3.8	16
130	The Analysis of Tryptase in Serum of Sarcoidosis Patients. Inflammation, 2009, 32, 310-314.	3.8	15
131	Nonâ€invasive biomarkers in pulmonary fibrosis. Respirology, 2009, 14, 788-795.	2.3	68
132	Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases. American Journal of Pathology, 2009, 174, 1683-1691.	3.8	59
133	Low Incidence of Pulmonary Graft-Versus-Host Disease in Older Patients After Reduced Toxicity Conditioning with FBM Prior to Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 4660-4660.	1.4	0
134	Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma. Respirology, 2008, 13, 1022-1027.	2.3	12
135	Genetics of Sarcoidosis. Clinics in Chest Medicine, 2008, 29, 391-414.	2.1	80
136	Eosinophilic cationic protein in bronchoalveolar lavage fluid of lung transplant patients. Clinical Chemistry and Laboratory Medicine, 2008, 46, 563-4.	2.3	3
137	Phenotyping Sarcoidosis from a Pulmonary Perspective. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 330-336.	5.6	137
138	Sarcoidosis-Immunopathogenetic Concepts. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 003-014.	2.1	86
139	IL-10â€“producing monocytes differentiate to alternatively activated macrophages and areÂincreased in atopic patients. Journal of Allergy and Clinical Immunology, 2007, 119, 464-471.	2.9	55
140	CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 1685-1693.	6.7	202
141	A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 781-792.	5.6	403
142	CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. Respiratory Research, 2005, 6, 75.	3.6	43
143	Zafirlukast Improves Asthma Control in Patients Receiving High-Dose Inhaled Corticosteroids. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 578-585.	5.6	198
144	Acute exacerbations. , 0, , 143-150.		1

#	Article	IF	Citations
145	Therapie der Lungenfibrosen: InterdisziplinÃre Diagnostik bessert Therapiechancen. , 0, , .		0